EUVIMEDEUVIMED entdecken
Crossref

External Quality Assessment for Unfractionated Heparin Monitoring: An Update from Australasia/Asia-Pacific

Emmanuel J Favaloro iD, Sandya Arunachalam, Leonardo Pasalic iD

Seminars in Thrombosis and Hemostasis · 01.11.2026 · 52 (08) · 956-966

DOI: 10.1055/a-2779-0035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Seminars in Thrombosis and Hemostasis, erschienen am 01.11.2026. Verfasst von Emmanuel J Favaloro und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research, Westmead Hospital, We…. Hauptthemen laut MEDLINE: Anticoagulants, Drug Monitoring, Heparin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Unfractionated heparin (UFH) remains a major anticoagulant therapy applied within the acute hospital system. Due to intra- and interpatient variability, UFH monitoring needs to be applied to ensure patients remain free of thrombotic and bleeding complications at too low and too high an UFH level, respectively. Monitoring of UFH therapy is usually achieved using either an activated partial thromboplastin time (aPTT) or an anti-factor Xa (anti-Xa) method. The former is a clotting assay that evaluates both the anti-factor IIa (anti-IIa or anti-thrombin) and anti-Xa anticoagulant activity of UFH and the latter is a chromogenic assay that evaluates just the anti-Xa anticoagulant activity of UFH. The aPTT method is perhaps more widely utilized since aPTT testing is performed by all hemostasis laboratories performing routine coagulation tests. However, the aPTT method requires establishment of an aPTT UFH therapeutic range. The anti-Xa method is favored in larger hospital sites and by most experts and uses a standard UFH therapeutic range. We report findings for aPTT and anti-Xa testing for UFH monitoring in our geographic region using recent data (testing for the past 5 years; 2020–2024 inclusive) from the Royal College of Pathologists of Australasia Quality Assurance Program, an international external quality assessment (EQA) program, with over 110 enrolments for this EQA module. Four samples are assessed each year, with these comprising various levels of UFH. Good reproducibility was observed for duplicate samples sent in different surveys. Coefficient of variation (%) data revealed moderate variation for samples containing UFH (10–40% for anti-Xa; 10–25% for aPTT). Anti-Xa reagents containing dextran sulphate tended to yield higher anti-Xa values than those without. Interpretations regarding UFH levels being below, within, or above therapeutic levels were generally reported as expected, according to the level of UFH present in the sample, especially for anti-Xa testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsDrug MonitoringHeparinHumansAustralasiaBlood Coagulation TestsFactor Xa InhibitorsPartial Thromboplastin Time

Substanzen

AnticoagulantsFactor Xa InhibitorsHeparin

Autor:innen und Institutionen

  • Department of Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia.
  • Sydney Centres for Thrombosis and Haemostasis, Research and Education Network, Westmead Hospital, Westmead, New South Wales, Australia.
  • Faculty of Science and Health, Charles Sturt University, Wagga Wagga, New South Wales, Australia.
  • School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia.
  • RCPAQAP Haematology, St. Leonards, New South Wales, Australia.
  • Westmead Clinical School, University of Sydney, Westmead Hospital, Westmead, NSW, Australia.

ORCID-Profile: Emmanuel J Favaloro, Leonardo Pasalic

Zitieren

APA

Favaloro, E. J., Arunachalam, S., & Pasalic, L. (2026). External Quality Assessment for Unfractionated Heparin Monitoring: An Update from Australasia/Asia-Pacific. Seminars in Thrombosis and Hemostasis, 52(08), 956-966. https://doi.org/10.1055/a-2779-0035

Vancouver

Favaloro EJ, Arunachalam S, Pasalic L. External Quality Assessment for Unfractionated Heparin Monitoring: An Update from Australasia/Asia-Pacific. Seminars in Thrombosis and Hemostasis. 2026;52(08):956-966. doi:10.1055/a-2779-0035

BibTeX
@article{Favaloro2026,
  author = {Favaloro, Emmanuel J and Arunachalam, Sandya and Pasalic, Leonardo},
  title = {External Quality Assessment for Unfractionated Heparin Monitoring: An Update from Australasia/Asia-Pacific},
  journal = {Seminars in Thrombosis and Hemostasis},
  year = {2026},
  volume = {52},
  number = {08},
  pages = {956--966},
  doi = {10.1055/a-2779-0035}
}
Kostenlos starten →